Related Experiment Videos
[Bedside thrombelastography. Cost reduction in cardiac surgery]
G J Spalding1, M Hartrumpf, T Sierig
1Herzchirurgie, Herzzentrum Brandenburg, Ladeburger Strasse 17, 16321 Bernau bei Berlin. g.spalding@immanuel.de
Insights
Implementing bedside rotational thromboelastometry (ROTEM) significantly reduced blood product costs in cardiac surgery. This cost-effective approach improved coagulation management and decreased overall expenditure.
Area of Science:
- Cardiovascular Surgery
- Anesthesiology
- Transfusion Medicine
Background:
- Increasing costs of blood and coagulation products in cardiac surgery due to demographic changes and antiplatelet medication.
- Need for effective strategies to manage perioperative coagulation and control expenditure.
Purpose of the Study:
- To evaluate the cost-effectiveness of bedside rotational thromboelastometry (ROTEM) in cardiac surgery.
- To analyze the impact of ROTEM on the use of blood products and coagulation factors.
- To develop a cost-effective treatment algorithm for perioperative coagulation disorders.
Main Methods:
- Retrospective analysis of annual treatment costs for cardiosurgical patients before and after ROTEM implementation.
- Assessment of cumulative numbers and costs of platelet concentrates (PltC), fresh frozen plasma (FFP), red blood cell units (RBC), and coagulation factors (PCC, rFVIIa, FXIII, fibrinogen).
- Comparison of average monthly costs, rethoracotomies, and early mortality between the two periods.
Main Results:
- ROTEM implementation led to a 25% decrease in RBC and 50% decrease in PltC expenditure.
- Significant reductions in prothrombin complex concentrates (PCC) and factor XIII (FXIII) by 80%, with complete omission of rFVIIa.
- Overall blood product costs decreased by 32% and coagulation factor costs by 50%, resulting in combined savings of 44%, outweighing ROTEM expenses.
- Rethoracotomies decreased from 6.6% to 5.5%, while early mortality remained stable.
Conclusions:
- Bedside ROTEM analysis enables selective substitution management, significantly reducing costs for perioperative coagulation disorders.
- Cost savings from reduced blood and coagulation product use substantially exceed ROTEM implementation costs.
- Differential coagulation management guided by ROTEM is a cost-effective strategy in cardiac surgery.
Background:
Demographic changes and aggressive medication with platelet aggregation inhibitors have resulted in a marked increase in blood and coagulation product expenditure and costs in cardiac surgery. We analyzed the bedside coagulation test (ROTEM) in order to verify clot forming quality and to find a cost-effective treatment algorithm.
Patients And Methods:
Annual treatment costs of all cardiosurgical patients were retrospectively analyzed before (729 patients) and after (693 patients) implementation of the bedside ROTEM test. Cumulative numbers and costs of platelet concentrates (PltC), fresh frozen plasma (FFP), red blood cell units (RBC), and the coagulation factors prothrombin complex concentrates (PCC), recombinant factor VIIa (rFVIIa), factor XIII (FXIII), and fibrinogen were assessed. Average monthly numbers and costs were compared. The number of rethoracotomies and early mortality were assessed and compared in both periods.
Results:
After ROTEM implementation cumulative RBC expenditure showed a 25% decrease and PltC a 50% decrease. FFP expenditure remained unchanged. PCC, FXIII were markedly reduced (-80%) while rFVIIa was entirely omitted. Fibrinogen, however, showed a two-fold increase. Cumulative average monthly costs of all blood products decreased from 66,000 EUR to 45,000 EUR (-32%). Coagulation factor average monthly costs decreased from 60,000 EUR to 30,000 EUR (-50%) yielding combined savings of 44%. In contrast, average monthly costs for ROTEM were 1,580 EUR. The total number of rethoracotomies decreased from 6.6% to 5.5% while early mortality (5.9%; 6.0%) remained stable.
Conclusions:
Cumulative costs for treatment of perioperative coagulation disorders were reduced by bedside ROTEM analysis to achieve a selective substitution management. Saved costs for blood and coagulation products clearly outweighed the expenses of ROTEM. Adequate differential coagulation management can therefore be cost-effective.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Imaging Studies for Cardiovascular System V: CT